Sixth International Symposium on Hormonal Oncogenesis

第六届激素肿瘤发生国际研讨会

• 批准号: 8006177
• 负责人: Jonathan J. Li
• 金额: $ 0.55万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8006177
• 关键词: Address; Affect; Basic Science; Books; Breast; Cells; Characteristics; Clinical; Clinical Research; Collaborations; Country; Development; Discipline; Endocrine; Epidemiology; Etiology; Fostering; Goals; Growth Factor; Hormonal; Hormones; International; Malignant Neoplasms; Mediating; Mitosis; Molecular; Molecular Target; Nature; Neoplasms; New York; Oral; Play; Preventive; Process; Prognostic Marker; Prostate; Publishing; Recurrent disease; Research Personnel; Resistance; Role; Schedule; Solutions; Stem cells; Steroids; Structure; Tissues; Translational Research; Woman; anticancer research; cancer risk; improved; interest; lectures; malignant phenotype; meetings; men; novel; novel diagnostics; peptide hormone; posters; prevent; programs; public health relevance; research study; stem; symposium; treatment strategy; tumor progression; tumorigenesis

DESCRIPTION (provided by applicant): The primary goal of the 6th INTERNATIONAL SYMPOSIUM ON HORMONAL ONCOGENESIS (ISHO) is to promote an understanding of the role of steroid and peptide hormones, as well as, growth factors involved in mediating the downstream molecular targets that effect the onset, propagation, and progression of cells contained within endocrine-associated target tissues to malignancy. Hormonally associated cancers comprise ~30% of all cancers occurring in women (breast) and in men (prostate). Moreover, there is growing evidence that hormones can affect the progression of cancers that are not normally considered to be under significant endocrine involvement. To attain this goal, the salient characteristics of the upcoming ISHO are multi-disciplinary and translational. An assembly of speakers and attendees of different scientific and clinical backgrounds will be gathered with a common interest in hormonally-related cancer whose ultimate goal is to improve both preventive and treatment strategies by increasing our understanding of the cellular and molecular processes which underline its progress and the role that hormones play in cancer development. The program aim is to identify the development of a malignant phenotype and implement the use of specific agents on novel molecular targets to prevent cancer development and in the treatment of primary and recurrent disease. The intent of this ISHO is to provide cutting edge progress in cancer research in the field of hormonal oncogenesis with an emphasis in translational research studies. The following sessions are proposed: SESSION I. Stem/Progenitor Cells. SESSION II. Targeting Early Pre-invasive Hormonal Cancers. SESSION III. Deregulation of Mitosis. SESSION IV. New Diagnostic and Prognostic Markers for Hormonal Cancer Risk. SESSION V. Microenvironment in Neoplasia. SESSION VI. Novel Paradigms and Therapies in Hormonal Cancers. Additionally, there will be one PLENARY and three STATE OF THE ART lectures, as well as two Poster Sessions, of which a limited number of oral presentations will be scheduled to be discussed by all attendees. The proceedings of the ISHO will be published in a book from Springer, New York, as has been the case of all past symposia. The diversity of the disciplines presented by speakers, the attendee's discussions, and the intimate nature because of size and structure of these symposia have uniquely fostered subsequent collaborations among different investigators that normally would not come together in other scientific meetings, thus greatly accelerating finding solutions for these important cancers.

描述（由申请人提供）：第六届激素致癌作用国际研讨会 (ISHO) 的主要目标是促进对类固醇和肽激素以及参与介导下游分子靶点影响的生长因子的作用的了解内分泌相关靶组织内细胞的发生、增殖和进展为恶性肿瘤。 与激素相关的癌症约占女性（乳腺癌）和男性（前列腺）所有癌症的 30%。 此外，越来越多的证据表明，激素可以影响通常不被认为与内分泌有显着关系的癌症的进展。 为了实现这一目标，即将到来的 ISHO 的显着特点是多学科和转化性。 具有不同科学和临床背景的演讲者和与会者将聚集在一起，对与激素相关的癌症有共同的兴趣，其最终目标是通过增加我们对细胞和分子过程的理解来改善预防和治疗策略，这些过程强调了其进展和激素在癌症发展中的作用。该计划的目的是确定恶性表型的发展，并在新的分子靶点上使用特定药物来预防癌症的发展以及治疗原发性疾病和复发性疾病。该 ISHO 的目的是提供激素肿瘤发生领域癌症研究的前沿进展，重点是转化研究。 建议召开以下会议： 第一节：干/祖细胞。 第二场会议。 针对早期浸润前激素癌症。 第三场会议。 有丝分裂的失调。 第四场会议。 激素癌症风险的新诊断和预后标志物。 第五节。肿瘤的微环境。 第六场会议。 激素癌症的新范式和疗法。 此外，还将举行一场全体会议和三场最新技术讲座，以及两场海报会议，其中将安排有限数量的口头演讲供所有与会者讨论。 与过去所有研讨会的情况一样，ISHO 的会议记录将在纽约斯普林格出版的一本书中出版。 演讲者介绍的学科多样性、与会者的讨论以及由于这些研讨会的规模和结构而产生的亲密性质，独特地促进了不同研究人员之间的后续合作，而这些合作通常不会在其他科学会议上聚集在一起，从而大大加快了寻找解决方案的速度这些重要的癌症。